Modulation of MHC class II antigen expression in human myoblasts after treatment with IFN-gamma.
Some investigators have proposed myoblast transfer as a potential therapy for the treatment of Duchenne muscular dystrophy. Little is known about the immunobiology of myoblast transplantation. Transplantation rejection is mediated to a large extent by CD8+ T cells, which recognize alloantigens encoded by class I HLA genes, and by CD4+ T cells, which recognize alloantigens encoded by class II HLA genes. Gamma interferon (IFN-gamma) is a potent inducer of HLA class II molecules as well as beta 2-microglobulin, which is co-expressed with HLA class I. IFN-gamma may be a critical cytokine involved in graft rejection. We purified human myoblasts by flow cytometry and incubated them in vitro for varying time periods with recombinant human IFN-gamma. The inducibility of HLA-DR and -DP molecules raises a note of caution concerning possible rejection phenomenon which might occur following myoblast transplantation.
Mantegazza
R
R
Department of Neurology and Neurological Sciences, Stanford University, CA 94305-5235.
Hughes
S M
SM
Mitchell
D
D
Travis
M
M
Blau
H M
HM
Steinman
L
L
D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D015395:Histocompatibility Antigens Class I / Q000276:immunology; D000949:Histocompatibility Antigens Class II / Q000235:genetics / Q000276:immunology*; D006801:Humans; D007371:Interferon-gamma / Q000494:pharmacology*; D009132:Muscles / Q000166:cytology / Q000196:embryology / Q000276:immunology*; D009994:Osmolar Concentration; D016133:Polymerase Chain Reaction; D014158:Transcription, Genetic
D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II; D007371:Interferon-gamma